BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mortezaee K. Organ tropism in solid tumor metastasis: an updated review. Future Oncology 2021;17:1943-61. [DOI: 10.2217/fon-2020-1103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Mortezaee K, Majidpoor J, Najafi S. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. Life Sciences 2022;310:121083. [DOI: 10.1016/j.lfs.2022.121083] [Reference Citation Analysis]
2 Mortezaee K, Majidpoor J. Cellular immune states in SARS-CoV-2-induced disease. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1016304] [Reference Citation Analysis]
3 Mortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol 2022;39:193. [PMID: 36071302 DOI: 10.1007/s12032-022-01801-0] [Reference Citation Analysis]
4 Giusto E, Žárská L, Beirne DF, Rossi A, Bassi G, Ruffini A, Montesi M, Montagner D, Ranc V, Panseri S. Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy. Nanomaterials 2022;12:2372. [DOI: 10.3390/nano12142372] [Reference Citation Analysis]
5 Mortezaee K, Majidpoor J. Dysregulated metabolism: A friend-to-foe skewer of macrophages. International Reviews of Immunology. [DOI: 10.1080/08830185.2022.2095374] [Reference Citation Analysis]
6 Mortezaee K, Majidpoor J. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. Med Oncol 2022;39:131. [PMID: 35716327 DOI: 10.1007/s12032-022-01735-7] [Reference Citation Analysis]
7 Mortezaee K, Majidpoor J. Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy. Cell Oncol (Dordr) 2022. [PMID: 35587857 DOI: 10.1007/s13402-022-00667-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 AlGhamdi H, Dhont J, Krayem M, De Bruyn P, Engels B, Van Gestel D, Van den Begin R. The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers (Basel) 2022;14:2046. [PMID: 35454951 DOI: 10.3390/cancers14082046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Mortezaee K, Majidpoor J. Checkpoint inhibitor/interleukin-based combination therapy of cancer. Cancer Med 2022. [PMID: 35301813 DOI: 10.1002/cam4.4659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Randhawa G, Jb D, Kaur K. Exophytic Mass Around the Tip of the Nose: Unusual Presentation of Metastatic Renal Cell Carcinoma. Cureus. [DOI: 10.7759/cureus.23113] [Reference Citation Analysis]
12 Hobani YH. Cytotoxicity of Mahanimbine from Curry Leaves in Human Breast Cancer Cells (MCF-7) via Mitochondrial Apoptosis and Anti-Angiogenesis. Molecules 2022;27:971. [PMID: 35164236 DOI: 10.3390/molecules27030971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
14 Mortezaee K, Majidpoor J. The impact of hypoxia on immune state in cancer. Life Sci 2021;286:120057. [PMID: 34662552 DOI: 10.1016/j.lfs.2021.120057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
15 Mortezaee K, Majidpoor J. Key promoters of tumor hallmarks. Int J Clin Oncol 2021. [PMID: 34773527 DOI: 10.1007/s10147-021-02074-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
16 Majidpoor J, Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomed Pharmacother 2021;145:112419. [PMID: 34781146 DOI: 10.1016/j.biopha.2021.112419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
17 Majidpoor J, Mortezaee K. Interleukin-2 therapy of cancer-clinical perspectives. Int Immunopharmacol 2021;98:107836. [PMID: 34218217 DOI: 10.1016/j.intimp.2021.107836] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
18 Mortezaee K. Normalization in tumor ecosystem: Opportunities and challenges. Cell Biol Int 2021. [PMID: 34189798 DOI: 10.1002/cbin.11655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
19 Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. [PMID: 34004256 DOI: 10.1016/j.lfs.2021.119627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]